

carbon atoms in length, alkyl glycoside, cyclodextrin or derivative thereof, salt of a glycyrrhizine acid, salt of a saponin glycoside, salt of an acyl carnitine, and sodium salicylate.

I1
Amended
2. (Amended) ^{excipient} A composition as claimed in claim 1, including said one or more non-hygroscopic excipients, said one or more non-hygroscopic excipients comprising a carrier that comprises either

(a) particles having a diameter of less than 10 microns or equal to about 10 microns, such that at least 50% of said composition consists of primary particles having a diameter of less than 10 microns or equal to about 10 microns; or

(b) coarse particles having a diameter of at least 20 microns, such that an ordered mixture is formed between (i) the carrier and (ii) the polypeptide of (A) and the one or more surfactant compounds of (B).

I2
9/52
21. (Amended) A method for systemic administration of a biologically active polypeptide, comprising providing composition of claim 1; and causing said patient to inhale said composition from a dry powder inhaler device.

I3
29. (Amended) The method of claim 21 wherein the surfactant compound is a salt of a fatty acid.

9/53
30. (Amended) The method of claim 29 wherein the surfactant compound is sodium caprate.

I4
9/54
56. (Amended) The method of claim 21, wherein said surfactant compound is a bile salt derivative, an alkyl glycoside, a cyclodextrin or derivative thereof, or a phospholipid.

I5
9/55
59. (Amended) The method of claim 21, wherein said surfactant compound is a bile salt.

I6
78. (Amended) A dry powder inhaler device containing the composition of claim 1.

I751 89. (Amended) The dry powder inhaler device of claim 78, wherein said surfactant compound is a bile salt derivative, an alkyl glycoside, a cyclodextrin or derivative thereof, or a phospholipid.

90. (Amended) The dry powder inhaler device of claim 78, wherein said surfactant compound is a salt of a fatty acid.

I8 93. (Amended) The dry powder inhaler device of claim 78, wherein said surfactant compound is sodium caprate.

458 94. (Amended) The dry powder inhaler device of claim 78, wherein said surfactant compound is a bile salt.

I9 96. (Amended) The dry powder inhaler device of claim 78, wherein said primary particles are formed into agglomerates, said device being configured to induce the majority of said agglomerates to break down into particles having a diameter less than 10 microns or equal to about 10 microns, upon inhalation of said agglomerates from said device. --